Associations with immune markers and the consensus molecular subtypes are inconsistent.<h4>Discussion</h4>A lower prevalence of mutations in <i>KRAS</i> and <i>BRAF</i> is consistent with extended survival and superior response to targeted therapies for metastatic disease. This evidence concerns the gene KRAS and metastatic neoplasm.